Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair

Accomplished CFO and Board Leader to Provide Independent Leadership to Deliver on Company’s Growth Strategy

BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board director and audit chair. Ms. Reeve brings to Cardurion more than 25 years of global financial leadership and board experience across pharmaceutical, medical device and biopharma companies.

Most recently, Ms. Reeve served as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, where she led a 2018 public offering and oversaw the company’s 2021 sale to MorphoSys AG for $1.7 billion. Prior to Constellation, she acted as interim Chief Financial Officer of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance and investor relations and helped lead a $5 billion take private transaction by Pamplona Capital Management. Earlier in her career, she served as Chief Financial Officer of both Inotek Pharmaceuticals and Aton Pharma and held senior finance roles in major pharmaceutical companies, including Novartis, Merck and Bristol Myers Squibb.

“We are fortunate to welcome a leader of Emma’s experience and caliber to our Board at this exciting inflection point in Cardurion’s growth journey. As a seasoned life sciences executive with deep expertise in finance, capital markets and corporate strategy, Emma brings tremendous perspective to Cardurion’s Board,” said Michael E. Mendelsohn, M.D., Founder and Chairman of Cardurion. “We look forward to collaborating with Emma as Cardurion advances our two groundbreaking clinical programs in PDE9 and CaMKII inhibition and continues to address other unmet needs for patients with cardiovascular disease.”

Ms. Reeve currently serves as board chair at Editas Medicine, and as a board director at PTC Therapeutics, Aadi Bioscience and Ribon Therapeutics. She is also a member of the board of Trustees of Tufts Medical Center. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London, and is an associate of the Institute of Chartered Accountants in England & Wales.

“I am impressed with the bold and innovative approach Cardurion is taking to help patients suffering from and at risk for cardiovascular disease,” said Ms. Reeve. “I am excited to contribute to the Company’s mission to advance novel cardiovascular drug candidates while building on its strong foundation and industry-leading expertise.”

About Cardurion Pharmaceuticals
Cardurion is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Cardurion was founded by physician-scientists with world-class expertise in cardiovascular signaling pathways, and a shared passion to find and develop a pipeline of novel treatment options to improve the lives of patients. Cardurion has two groundbreaking clinical programs in development, a PDE9 program targeting heart failure and the first ever CaMKII inhibitor in clinical development targeting multiple cardiovascular indications.

Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at https://cardurion.com.

Media:
Scott Lessne
Stanton
646-502-3569
slessne@stantonprm.com